<code id='42113A388A'></code><style id='42113A388A'></style>
    • <acronym id='42113A388A'></acronym>
      <center id='42113A388A'><center id='42113A388A'><tfoot id='42113A388A'></tfoot></center><abbr id='42113A388A'><dir id='42113A388A'><tfoot id='42113A388A'></tfoot><noframes id='42113A388A'>

    • <optgroup id='42113A388A'><strike id='42113A388A'><sup id='42113A388A'></sup></strike><code id='42113A388A'></code></optgroup>
        1. <b id='42113A388A'><label id='42113A388A'><select id='42113A388A'><dt id='42113A388A'><span id='42113A388A'></span></dt></select></label></b><u id='42113A388A'></u>
          <i id='42113A388A'><strike id='42113A388A'><tt id='42113A388A'><pre id='42113A388A'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:544
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more
          The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO
          The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

          MollyFerguson/STATHappyGroundhogDayeve.SometakesandthoughtsonBluebirdBio’squestforgenetherapyprofits

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Top private equity targets in 2023: cardiology, clinical trials, lasers

          AdobeBysomemeasures,privateequityinvestmentlaggedin2023,ayearmarkedbygrowingdistressandhigh-profiled